SARC011

A Study of R1507 in Participants With Recurrent or Refractory Sarcoma

TYPE OF SARCOMA: Ewing’s sarcoma, osteosarcoma, synovial sarcoma, rhabdomyosarcoma, alveolar soft part sarcoma, desmoplastic small round cell tumor, extraskeletal myxoid chondrosarcoma, clear cell sarcoma
DRUG: R1507

ACCRUAL STATUS: Completed

OVERALL STUDY PRINCIPAL INVESTIGATORS:
Alberto Pappo, MD
Texas Children’s Cancer Center

Pr Gilles Vassal
Institut Gustave Roussy

CLINICALTRIALS.GOV IDENTIFIER: NCT00642941

FOR STUDY DETAILS AND ELIGIBILITY CRITERIA: CLINICALTRIALS.GOV

PUBLICATIONS:
Koshkin VS, Bolejack V, Schwartz LH, Wahl RL, Chugh R, Reinke DK, Zhao B, O JH, Patel SR, Schuetze SM, Baker LH. Assessment of Imaging Modalities and Response Metrics in Ewing Sarcoma: Correlation With Survival. J Clin Oncol. 2016 Oct 20;34(30):3680-3685. doi: 10.1200/JCO.2016.68.1858. PMID: 27573658; PMCID: PMC5065114.

Pappo AS, Vassal G, Crowley JJ, Bolejack V, Hogendoorn PC, Chugh R, Ladanyi M, Grippo JF, Dall G, Staddon AP, Chawla SP, Maki RG, Araujo DM, Geoerger B, Ganjoo K, Marina N, Blay JY, Schuetze SM, Chow WA, Helman LJ. A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: results of a Sarcoma Alliance for Research Through Collaboration study. Cancer. 2014 Aug 15;120(16):2448-56. doi: 10.1002/cncr.28728. Epub 2014 May 2. PMID: 24797726; PMCID: PMC7009782.

To learn more about this study or to contact the study research staff: